Biotech

All Articles

Actinogen's cortisol blocker fails phase 2 anxiety research

.Actinogen Medical's cortisol blocker has missed out on the primary endpoint of a period 2 research ...

Bivictrix determines going private only technique to take ADC into facility

.Antibody-drug conjugates (ADCs) have actually been at the facility of many a billion-dollar biobuck...

TPG tops up funds to $580M for assets around life scientific researches

.Resource supervisor TPG, which has actually assisted biotechs such as Sionna Rehabs and also Santa ...

Merck quits stage 3 TIGIT trial in bronchi cancer for futility

.Merck &amp Co.'s TIGIT plan has gone through an additional obstacle. Months after shuttering a phas...

After a challenging year, Exscientia folds up in to Recursion

.After a year defined through pipeline hairstyles, the variation of its own chief executive officer ...

Cullinan, after $25M offer, restore bispecific to Port

.Cullinan Therapeutics was excited sufficient along with Port BioMed's bispecific invulnerable react...

A closer take a look at Brutal Biotech's Ferocious 15

.Within this week's incident of "The Best Line," our experts are actually diving right into Intense ...

Lilly deals with phase 2 breakdown of tau-targeting med

.The confetti is still soaring coming from Eli Lilly's event celebrating the approval of Alzheimer's...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Accept to recently's Chutes &amp Ladders, our summary of significant management hirings, firings as...

Lykos will talk to FDA to reassess its decision following rejection of MDMA treatment for post-traumatic stress disorder

.Adhering to a bad showing for Lykos Therapeutics' MDMA applicant for trauma at a current FDA advisi...